Trials / Completed
CompletedNCT04057131
FIRAZYR General Drug Use-Results Survey (Japan)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 179 (actual)
- Sponsor
- Shire · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The objectives of this survey are to collect data to report the safety and efficacy of Firazyr (Icatibant acetate) in the post-marketing phase in participants diagnosed with Hereditary Angioedema (HAE).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Firazyr | Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information. |
Timeline
- Start date
- 2018-11-20
- Primary completion
- 2024-07-29
- Completion
- 2024-07-29
- First posted
- 2019-08-15
- Last updated
- 2025-02-21
- Results posted
- 2025-02-21
Locations
18 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04057131. Inclusion in this directory is not an endorsement.